Corvus Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Ph…

Biotechnology
US, Burlingame [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Corvus Pharmaceuticals, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Corvus Pharmaceuticals, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Corvus Pharmaceuticals, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of CRVS's Analysis
CIK: 1626971 CUSIP: 221015100 ISIN: US2210151005 LEI: - UEI: -
Secondary Listings
CRVS has no secondary listings inside our databases.